Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
18,515
archived clinical trials in
Lymphoma

Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph
mi
from
St. Joseph, MI
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Lakeland Cancer Care Center at Lakeland Hospital - St. Joseph
mi
from
St. Joseph, MI
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
University of Minnesota Medical Center, Fairview
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Missouri Cancer Associates
mi
from
Columbia, MO
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Missouri Cancer Associates
mi
from
Columbia, MO
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
St Louis, MO
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Siteman Cancer Center at Barnes-Jewish Hospital
mi
from
St Louis, MO
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center
mi
from
Grand Island, NE
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center
mi
from
Grand Island, NE
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Great Plains Regional Medical Center
mi
from
North Platte, NE
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Great Plains Regional Medical Center
mi
from
North Platte, NE
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
UNMC Eppley Cancer Center at the University of Nebraska Medical Center
mi
from
Omaha, NE
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Cancer Institute of New Jersey at Cooper - Voorhees
mi
from
Voorhees, NJ
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Charles R. Wood Cancer Center at Glens Falls Hospital
mi
from
Glens Falls, NY
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Charles R. Wood Cancer Center at Glens Falls Hospital
mi
from
Glens Falls, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
New York Weill Cornell Cancer Center at Cornell University
mi
from
New York, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
CCOP - Hematology-Oncology Associates of Central New York
mi
from
Syracuse, NY
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
CCOP - Hematology-Oncology Associates of Central New York
mi
from
Syracuse, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
SUNY Upstate Medical University Hospital
mi
from
Syracuse, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Community General Hospital
mi
from
Syracuse, NY
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Community General Hospital
mi
from
Syracuse, NY
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Presbyterian Cancer Center at Presbyterian Hospital
mi
from
Charlotte, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Wayne Memorial Hospital, Incorporated
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Wayne Radiation Oncology
mi
from
Goldsboro, NC
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Wayne Radiation Oncology
mi
from
Goldsboro, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Lenoir Memorial Cancer Center
mi
from
Kinston, NC
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Lenoir Memorial Cancer Center
mi
from
Kinston, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Wilson Medical Center
mi
from
Wilson, NC
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Wilson Medical Center
mi
from
Wilson, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Wake Forest University Comprehensive Cancer Center
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Bon Secours St. Francis Health System
mi
from
Greenville, SC
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Bon Secours St. Francis Health System
mi
from
Greenville, SC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
CCOP - Greenville
mi
from
Greenville, SC
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
CCOP - Greenville
mi
from
Greenville, SC
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Mountainview Medical
mi
from
Berlin, VT
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Mountainview Medical
mi
from
Berlin, VT
Click here to add this to my saved trials
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated:  6/30/2016
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Phase II Trial of Doxorubicin, Vinblastine, and Gemcitabine (AVG) Chemotherapy for Non-Bulky Stage I and II Hodgkin's Lymphoma
Status: Enrolling
Updated: 6/30/2016
Fletcher Allen Health Care - University Health Center Campus
mi
from
Burlington, VT
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Los Angeles, CA
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Stanford, CA
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Washington,
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Washington,
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Atlanta, GA
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Chicago, IL
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Westwood, KA
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Westwood, KA
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Lexington, KY
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Lexington, KY
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Louisville, KY
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Baltimore, MD
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Detroit, MI
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Hackensack, NJ
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Hackensack, NJ
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
New York, NY
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Greenville, NC
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Greenville, NC
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Portland, OR
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Houston, TX
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Burlington, VT
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Burlington, VT
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
Clinical Research Facility
mi
from
Seattle, WA
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated:  7/11/2016
mi
from
Adelaide,
A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
An Open-Label, Multicenter, Single-Arm, Phase 2 Study of PCI-32765 (Ibrutinib) in Subjects With Refractory Follicular Lymphoma
Status: Enrolling
Updated: 7/11/2016
mi
from
Adelaide,
Click here to add this to my saved trials
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  7/11/2016
Long Beach Memorial Medical Center
mi
from
Long Beach, CA
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 7/11/2016
Long Beach Memorial Medical Center
mi
from
Long Beach, CA
Click here to add this to my saved trials
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated:  7/11/2016
University of Southern California
mi
from
Los Angeles, CA
PNT2258 for Treatment of Patients With r/r DLBCL (Wolverine)
A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Status: Enrolling
Updated: 7/11/2016
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials